Schlag G, Gaudernak T, Pelinka H, Redl H, Kuderna H, Poigenfürst J
Ludwig-Boltzmann-Institut für Experimentelle Traumatologie, Wien.
Unfallchirurgie. 1988 Feb;14(1):12-21.
The effect of either (randomized) Heparin/Dihydroergotamine (HDHE) or heparin-acenocoumarin (Hep/S) on the incidence of deep-vein thrombosis in the legs was studied in 212 women of more than 60 years of age with hip fractures. All patients were screened with the 125-I-fibrinogen uptake test (FUT) confirmed by a bilateral ascending venogram upon positive FUT. This revealed good sensitivity and specificity (85/84%) for the FUT. Deep vein thrombosis developed in 37.6% of the HDHE group and in 59.1% of the Hep/S group which was significantly different (p less than 0.005). The calculated thrombosis risk was significantly diminished (by 38% - p less than 0.005) in the HDHE group. Therefore we conclude that in traumatology Heparin/Dihydroergotamine seems to be the prophylaxis of choice.
对212名60岁以上髋部骨折的女性患者，研究了（随机分组的）肝素/双氢麦角胺（HDHE）或肝素/醋硝香豆素（Hep/S）对下肢深静脉血栓形成发生率的影响。所有患者均采用125-I-纤维蛋白原摄取试验（FUT）进行筛查，FUT结果阳性时通过双侧上行静脉造影加以确认。这显示FUT具有良好的敏感性和特异性（85/84%）。HDHE组深静脉血栓形成发生率为37.6%，Hep/S组为59.1%，二者差异显著（p<0.005）。HDHE组计算得出的血栓形成风险显著降低（降低38%，p<0.005）。因此我们得出结论，在创伤学领域，肝素/双氢麦角胺似乎是首选的预防药物。
